Mazen Darwazeh: Vice-Chairman and MENA CEO of Hikma Date of Interview: October 2013 Hikma is one of a handful of Jordanian companies that can truly be considered world class. In the first half of 2013, its revenues reached $638.3 million….
In a move that is set to transform its position in the US generics market, Hikma Pharmaceuticals has announced that it is acquiring Roxane Laboratories for JD1.88 billion ($2.65 billion) in cash and stock. Hikma, which was one of a number…
Hikma Pharmaceuticals is set this month to take its place alongside GlaxoSmithKline, AstraZeneca and Shire as a fourth blue-chip drug maker on the FTSE 100, Britain’s benchmark share index. Hikma will push Tullow Oil out of the esteemed club of…